Rosiglitazone monotherapy is effective in patients with type 2 diabetes.

@article{Lebovitz2001RosiglitazoneMI,
  title={Rosiglitazone monotherapy is effective in patients with type 2 diabetes.},
  author={Harold E. Lebovitz and Jo F Dole and Rita Patwardhan and Elizabeth B Rappaport and Martin I. Freed},
  journal={The Journal of clinical endocrinology and metabolism},
  year={2001},
  volume={86 1},
  pages={280-8}
}
This study evaluated the efficacy and safety of rosiglitazone monotherapy in patients with type 2 diabetes. After a 4-week placebo run-in period, 493 patients with type 2 diabetes were randomized to receive rosiglitazone [2 or 4 mg twice daily (bd)] or placebo for 26 weeks. The primary end point was change in hemoglobin A(1c); other variables assessed included fasting plasma glucose, fructosamine, endogenous insulin secretion, urinary albumin excretion, serum lipids, and adverse events… CONTINUE READING
Highly Influential
This paper has highly influenced 13 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 129 extracted citations

Pleiotropic effects of thiazolidinediones.

View 7 Excerpts
Highly Influenced

Studies on Incretins and Cardiovascular Function

Ala amide
2010
View 9 Excerpts
Highly Influenced

Rosiglitazone in Canada: experience in clinical practice.

Expert opinion on drug metabolism & toxicology • 2009
View 4 Excerpts
Highly Influenced

References

Publications referenced by this paper.
Showing 1-10 of 50 references

Rosiglitazone therapy is not associated with hepatotoxicity [ Abstract ]

A Salzman, J Patel
1999

Rosiglitazone therapy is not associated with hepatotoxicity [Abstract]. Diabetes. 48(Suppl 1):A95

A Salzman, J. Patel
1999
View 1 Excerpt

Thiazolidinediones: a new class of antidiabetic drugs.

Diabetic medicine : a journal of the British Diabetic Association • 1999
View 1 Excerpt

Similar Papers

Loading similar papers…